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Abstract 
Background: Circulating tumor cells (CTCs) detected in peripheral blood (PB) of cancer patients can be identified 
as isolated CTCs and circulating tumor microemboli (CTM). This study aimed to evaluate the prognostic value of CTM 
detection and CTC phenotype in advanced colorectal cancer (CRC) patients during chemotherapy.
Methods: A size-based platform for CTC isolation was applied. PB samples (5 ml) from 98 advanced CRC patients 
during 2–6 cycles chemotherapy were collected for CTC detection, and CTC count was correlated to patient’s clinico-
pathological characteristics and clinical outcome. And CTC phenotype was measured by immunofluorescent staining 
and evaluate the predictive significance on survival in 32 CTCs-positive patients with advanced CRC.
Results: Forty-eight of 98 patients were CTCs-positive, including 18 CTM-positive patients, and CTC detection was 
positively correlated with lymphatic invasion (P = 0.049), TNM stage (P = 0.023), and serum CEA level (P = 0.014). 
Moreover, Kaplan–Meier survival and Cox regression analyses revealed that the presence of CTCs was an independent 
factor for poor PFS and OS (P < 0.05) in advanced CRC patients during chemotherapy, and CTM-positive patients had 
shooter survival than isolated CTCs-positive patients (P < 0.05). Furthermore, patients with vimentin+ isolated CTCs/
CTM had shorter PFS and OS compared with CK+ CTCs (P < 0.05).
Conclusions: This study provided evidence that the presence of CTCs was positively correlated with poor prognosis, 
and furthermore, CTM and vimentin+ CTCs predicted poorer survival, which indicated that CTM and vimentin+ CTCs 
detected by a sensitive platform could be used to improve prognostic value of CTCs in advanced CRC patients under 
treatment.
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Background
Colorectal cancer (CRC) is the third most common 
cancer in male and the second most common in female 
worldwide, and contributes the fourth cause of cancer 
death in male and the third in female [1]. For advanced 
CRC patients, although many patients benefit from 
chemotherapy to some extent, for some patients exces-
sive chemotherapy was unnecessary due to inefficiency, 
moreover, multiple adverse effects seriously lower their 
life quality [2]. Therefore, new prognostic factors which 
could be used to identify patients who would benefit 
from chemotherapy are needed.
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Circulating tumor cells (CTCs) non-invasively isolated 
from peripheral blood can serve as a “liquid biopsy” and 
as a source of valuable tumor markers. Many studies 
reported that CTC detection had prognostic and thera-
peutic significance in CRC [3–7]. Moreover, in advanced 
CRC patients, the presence of CTCs before and during 
treatment had been proved to be an independent predic-
tor of progression-free survival (PFS) and overall survival 
(OS) [3, 6], and a key factor to improve the accuracy in 
assessing the effectiveness of first-line treatment [7].
However, CTC detection, enumeration and molecular 
characterization are quite challenging, because CTCs are 
rare in peripheral blood of patients. The Veridex CellSearch 
system (Veridex LLC, Raritan, NJ) utilizes magnetic beads 
coated by anti-EpCAM antibody to capture cells followed 
by the fluorescence staining to identify CTCs, defined as 
CK8/18/19+/DAPI+/CD45− cells [8]. However, EpCAM 
expression is dependent on the local microenvironment 
and is down-regulated in disseminated cells [9]. Epithelial-
mesenchymal transition (EMT) of tumor cells is induced in 
the bloodstream [10], which leads to mesenchymal tumor 
cells with stem-like phenotype [11, 12], and loss of epithe-
lial phenotype [13]. This is quite probably the reason why 
the CTC detection rates and counts in the CellSearch sys-
tem are generally low. For example, 17 of 66 non-metastatic 
CRC patients (26%) had ≥2 CTCs per 7.5  ml peripheral 
blood [14], and in another study, only 19 of 239 preopera-
tive CRC patients (~8%) had ≥1 CTC per 7.5 ml peripheral 
blood [15]. Therefore, CTCs as an independent prognostic 
marker, need a more sensitive method to further facilitate 
the evaluation of CTC detection.
Here, a sensitive size-based platform for CTC isola-
tion was applied, which could filter the hemocytes with 
small diameter and capture the tumor cells with relatively 
big diameter, followed by Romanowsky dye and immu-
nofluorescent staining to identify CTCs. In this study, 
peripheral blood samples (5 ml) from 98 advanced CRC 
patients during 2–6 cycles chemotherapy were collected 
to detect CTCs for Romanowsky dye staining, then CTC 
levels were correlated with clinicopathological charac-
teristics and patient’s survival. Moreover, CTC pheno-
type was measured by immunofluorescent staining in 32 
CTCs-positive patients with advanced CRC. It was dem-
onstrated that CTC detection by a size-based platform 
was positively correlated with lymphatic invasion, TNM 
stage, serum CEA level and poor survival, and CTM and 




Ninety-eight patients with advanced CRC during 2–6 
cycles chemotherapy were recruited in Cancer Center, 
Union Hospital, Huazhong university of science and 
technology, from January, 2013 to April, 2013, and 
peripheral blood samples from patients were collected. 
The TNM classification of CRC was based on Ameri-
can Joint Committee on Cancer (AJCC) 7th edition. 
The clinicopathologic characteristics of patients were 
classified according to the chart records, as showed in 
Table 1.
This prospective study was double-blinded in terms of 
blood draw, CTC detection and identification. For the 
purpose of this study, healthy donors were those without 
abnormal cells detected by this size-based platform for 
CTC isolation in peripheral blood.
The informed consent approved by ethics committee 
of Union Hospital, Huazhong university of science and 
technology had been obtained from all patients before 
examination. All procedures performed in studies involv-
ing human participants were in accordance with the ethi-
cal standards of the ethics committee of Union Hospital, 
Huazhong University of science and technology and with 
the Helsinki declaration and its later amendments or 
comparable ethical standards.
CTC detection by a size‑based platform
The 5  ml blood sample of advanced CRC patient was 
diluted up to 8  ml with 0.9% physiological saline con-
taining 0.2% paraformaldehyde, then measured on an 
automated testing platform following manufacturer’s 
instructions, as described in an earlier study by Vona 
et  al. [16]. This platform was composed of a membrane 
with 8  μm size pores and a automated testing device. 
The captured cells including abnormal cells and resid-
ual haemocytes on the membrane were stained with 
Romanowsky dye (eosin and methylene blue) and immu-
nofluorescent staining. The candidate CTCs were identi-
fied independently by 3 senior cytopathologists.
Immunofluorescent staining
The captured tumor cells on the membrane were pro-
cessed with Cytofix/Cytoperm Fixation/Permeabilization 
solution (BD, New Jersey, USA) for 10–15 min, incubated 
with 10% Goat Serum (Jackson, West Grove, USA) for 
30  min at room temperature, then incubated with anti-
CK8/18/19, anti-vimentin (Abcam Trading (Shanghai) 
Company Ltd., Shanghai, China) and anti-CD45 (Santa, 
Texas, USA) antibody overnight at 4  °C. The next day 
they were incubated with secondary antibodies, Alexa 
Fluor 488-conjugated goat anti-mouse, Alexa Fluor 
546-conjugated goat anti-rabbit, Cy5-conjugated goat 
anti-rabbit (InvitrogenTM, Thermo Fisher Scientific, 
Waltham, USA), and Hoechst (SIGMA, St. Louis, MO) 
for 1 h at room temperature. Then they were imaged by 
fluorescence microscope.
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Statistical analysis
All data were analyzed using SPSS 16.0 statistic software 
(SPSS Inc., Chicago, IL, USA). The associations between 
CTCs and clinicopathologic variables were evaluated 
with χ2 tests. Survival curves were calculated using the 
Kaplan–Meier method. Factors of prognostic significance 
were investigated with the univariate and multivariate 
Cox regression model. For all tests, the P ≤ 0.05 indicated 
statistical significance.
Results
Abnormal cells detected by a size‑based platform for CTC 
isolation in peripheral blood of patients with advanced 
CRC
In this study a size-based platform for CTC isolation was 
applied. This platform was mainly composed of a filter 
membrane with 8 μm size pores and an automated testing 
device. A spiking test was conducted to test the capture 
efficiency and sensitivity of this platform, in which HT29 
colorectal cancer cells were added into 5  ml peripheral 
blood of healthy donors. the transparent membrane in 
the filter got a clear background after CTC isolation and 
Romanowsky staining, which facilitated the procedure of 
indentifying CTCs and CTC phenotype (Fig. 1a, b). The 
results showed that this method for isolating CTCs was 
reliable and robust (Fig. 1c, d).
Based on the criteria proposed by other researchers 
[16–18] and our own experience, there were 6 criteria of 
cell morphological characteristics for evaluating abnor-
mal cells captured in peripheral blood: (1) the nuclear 
atypia: irregularity of nuclear shape, may be nodular or 
lobulated etc.; (2) a high nuclear–cytoplasmic ratio: >0.8; 
(3) a large cell diameter (the long diameter): >15  μm; 
(4) the hyperchromatic nuclei were dyed unevenly (due 
to the increase of chromatin and the thicker particles in 
cancer cells, the nucleus was hyperchromatic); (5) the 
thickened nuclear membrane was sunken, wrinkled and 
jagged; (6) the nuclear chromatin margination (nucleus 
side-shift), or a large nucleoli, or abnormal nuclear 
division.
Abnormal cells captured by this method were iden-
tified as CTCs in colorectal cancer, only if they met no 
less than 4 criteria above, or met the 6th criterion and 
any other 2 criteria (Fig.  1e, f ). If they met any 3 crite-
ria except the 6th criterion, or met only the 6th criterion, 
they were identified as the suspected CTCs (Fig. 1g, h). 
Besides, CTC cluster composed of three or more CTCs 
was recognized as circulating tumor microemboli (CTM) 
(Fig.  1i, j), while other cell clusters were recognized as 
the suspected CTM. However, some cells should not be 
present in peripheral blood normally (e.g. epithelial cells, 
endothelial cells) (Fig.  1k, l), or were of undetermined 
origin, all those cells were regarded as non-blood cells.
The relationship between CTCs/CTM 
and clinicopathological characteristics in advanced CRC 
with treatment
In this study, ninety-eight advanced CRC patients dur-
ing 2–6 cycles chemotherapy were subjected to CTC 
Table 1 Relationship between  circulating tumor cells 
(CTCs) and clinicopathological characteristics in advanced 
colorectal cancer
Italic values indicate statistically significant associations
* P ≤ 0.05
Characteristics No. of patients (%) CTCs P value
Positive Negative
All patients 98 (100) 48 (49.0) 50 (51.0)
Gender
Male 61 (62.2) 31 (50.8) 30 (49.2) 0.640
Female 37 (37.8) 17 (45.9) 20 (54.1)
Age (median 52, years)
<60 60 (61.2) 30 (50.0) 30 (50.0) 0.800
≥60 38 (38.8) 18 (47.4) 20 (52.6)
Tumor size (cm)
<5 43 (43.9) 20 (46.5) 23 (53.5) 0.666
≥5 55 (56.1) 28 (50.9) 27 (49.1)
Tumor location
Colon 58 (59.2) 29 (50.0) 29 (50.0) 0.808
Rectum 40 (40.8) 19 (47.5) 21 (52.5)
Histology differentiation
Poor 23 (23.5) 18 (78.3) 5 (21.7) 0.043*
Middle 54 (55.1) 23 (42.6) 31 (57.4)
Well 21 (21.4) 7 (33.3) 14 (66.7)
Depth of invasion
T1 + T2 15 (15.3) 6 (40.0) 9 (60.0) 0.135
T3 25 (25.5) 11 (44.0) 14 (56.0)
T4a 47 (48.0) 22 (46.8) 25 (53.2)
T4b 11 (11.2) 9 (81.8) 2 (18.2)
Lymphatic invasion
N0 30 (31.3) 12 (38.7) 19 (61.3) 0.049*
N1 22 (22.2) 7 (31.8) 15 (68.2)
N2a 22 (22.2) 13 (59.1) 9 (40.9)
N2b 24 (24.2) 16 (66.7) 8 (33.3)
TNM stage
III 17 (17.3) 4 (23.5) 13 (76.5) 0.023*
IVa 22 (22.5) 9 (40.9) 13 (59.1)
IVb 59 (60.2) 35 (59.3) 24 (40.7)
CEA (ng/ml)
≤10 54 (55.1) 20 (37.0) 34 (63.0) 0.014*
>10 44 (44.9) 28 (63.8) 16 (36.4)
CA199 (U/ml)
≤37 57 (58.2) 24 (42.1) 33 (57.9) 0.151
>37 41 (41.8) 24 (58.5) 17 (41.5)
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Fig. 1 Abnormal cells detected in peripheral blood (PB) of advanced CRC patients. a The clear background of a membrane in the filter after 
Romanowsky staining. b The spiking HT29 cells captured by the size-based platform for CTC isolation (as indicated by the black arrows). c The 
capture efficiency of cancer cell linces HT29, SKBR-3 and A549. d The sensitivity of isolating HT29 cells. e, f The single CTC (as indicated by the red 
arrows) detected in PB. g, h The suspected CTC (as indicated by the yellow arrows) in PB. i, j CTM (as indicated by the red arrows) detected in PB. k 
Epithelial cells (as indicated by the green arrows) detected in PB. l Endothelial cells (as indicated by the green arrows) detected in PB (a, ×10 magnifi-
cation; b, c, ×60 magnification; f–m, ×100 magnification)
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isolation and enumeration, forty-eight patients were 
CTCs-positive, including 18 CTM-positive patients. The 
association of CTCs with the clinicopathological variables 
of patients was shown in Table  1. CTCs were positively 
correlated with tumor de-differentiation (P = 0.004), lym-
phatic invasion (P = 0.049), TNM stage (P = 0.023), and 
serum CEA level (P = 0.014). By contrast, no significant 
association was found between CTCs-positive and other 
clinicopathological characteristics (P > 0.05 for all others), 
such as gender, age, tumor size, tumor location, serum 
CA199 level, and depth of invasion (Table 1). Serum CEA 
levels in CTCs-positive patients were higher than CTCs-
negative patients (334.8 ± 194.7 vs. 115.6 ± 71.43 ng/ml, 
P = 0.0155) (Fig. 2a), while there was no statistical signifi-
cance in serum CA199 levels between CTCs-positive and 
CTCs-negative patients (1486 ±  498.7 vs. 651.1 ±  339.2 
U/ml, P = 0.0887) (Fig. 2b).
Furthermore, CTC enumeration of all 98 advanced 
CRC patients ranged from 0 to 195 (mean  ±  SE: 
9.663 ± 2.775), and CTM enumeration ranged from 0 to 
17. And CTC enumeration was increasing with decreased 
tumor de-differentiation (poor vs. middle, P  =  0.0191; 
poor vs. high, P = 0.0359), increased lymphatic invasion 
(N2b vs. N0, P =  0.0429; N2b vs. N1, P =  0.0361; N2b 
vs. N2a, P = 0.1037), TNM stage (IVb vs. III, P = 0.0186; 
IVb vs. IVa, P = 0.1019) and serum CEA level (CEA > 10 
vs. CEA ≤ 10 ng/ml, P = 0.0026) (Fig. 2c–g).
CTCs/CTM predicted poor survival in advanced CRC 
patients under treatment
Based on univariate Cox regression analyses for all fac-
tors (Table  2), CTCs (P  <  0.0001), lymphatic invasion 
(P = 0.042), TNM stage (P < 0.001), and high CEA level 
(P  =  0.0027) were closely related with PFS. The multi-
variate Cox regression model further demonstrated that 
CTCs (P = 0.015) and TNM stage (P = 0.013) were inde-
pendent prognostic factors for shorter PFS (Table 2). And 
the Kaplan–Meier survival curves showed that CTCs-
positive patients with advanced CRC had a significantly 
unfavorable PFS (9 vs. 17 months, P = 0.0006) (Fig. 3a), 
and furthermore, CTM-positive patients had shorter 
PFS than CTCs-positive patients (6 vs. 12  months, 
P = 0.0052) (Fig. 3c).
Moreover, based on univariate Cox regression analy-
ses for all factors (Table 2), CTCs (P = 0.048), lymphatic 
invasion (P  <  0.001), and TNM stage (P  =  0.015) were 
closely related with poor OS. Although the multivari-
ate Cox regression model demonstrated that lymphatic 
invasion (P  <  0.001) and TNM stage (P  =  0.017) were 
independent prognostic factors for PFS but not CTCs 
(Table 2), the Kaplan–Meier survival curves showed that 
CTCs-positive patients with advanced CRC had a signifi-
cantly unfavorable OS (16.5 vs. 23 months, P =  0.0278) 
(Fig. 3b), and CTM-positive patients had worse OS than 
CTCs-positive patients (12 vs. 18  months, P  =  0.0228) 
(Fig. 3d).
Vimentin+ isolated CTCs/CTM predicted worse survival 
in advanced CRC patients under treatment
Thirty-two CTCs-positive patients were subjected to 
CTC isolation again to identify CTC phenotype by 
immunofluorescence. The samples were stained with 
anti-CK8/18/19 antibody (epithelial marker), anti-vimen-
tin antibody (mesenchymal marker), anti-CD45 antibody 
(for leukocytes), and hoechst (for nucleus). In this study, 
four CTC phenotypes were detected: CK+/Vimentin+/
CD45− CTM (Fig.  4a), CK−/Vimentin+/CD45− CTM 
(Fig.  4b), CK−/Vimentin+/CD45− isolated CTCs 
(Fig.  4c), and CK+/Vimentin−/CD45− isolated CTCs 
(Fig. 4d). For further analysis, 13 patients with vimentin+ 
CTCs/CTM (CK+/Vimentin+/CD45− CTM, CK−/
Vimentin+/CD45− CTM, CK−/Vimentin+/CD45− 
isolated CTCs) and 19 patients with CK+ CTCs (CK+/
Vimentin−/CD45− isolated CTCs) were identified. 
Interesting, it was found that all of CTM (detected in 11 
of 11 patients) were vimentin-positive, while most of the 
isolated CTCs (detected in 19 of 21 patients) were CK-
positive. Moreover, the Kaplan–Meier survival curves 
showed that advanced CRC patients with vimentin+ 
CTCs had significantly shorter PFS and OS compared 
with CK+ CTCs (6 vs. 11  months, P  =  0.0314; 11 vs. 
20 months, P = 0.0147) (Fig. 4e, f ).
Discussion
CTC detection in peripheral blood was recognized as 
“liquid biopsy” in solid tumors, because it could be per-
formed easily, frequently, and less invasively [19, 20]. 
There was increasing evidence which prove CTCs as 
the clinical marker for diagnostic, prognostic, and phar-
macologic purposes [21, 22]. Hence, CTC detection and 
characterization had become a research focus worldwide.
Although many studies about CTCs proved that high 
baseline CTC count was positively correlated with worse 
prognosis in colorectal cancer by CellSearch system [6, 
23, 24], the CTC detection rate and count in CellSearch 
system were generally low, and many approaches of CTC 
isolation had been developed recently. In this study, we 
applied a size-based platform for CTC isolation, and the 
spiking tests showed the capture efficiency and sensitiv-
ity of this platform was reliable and robust. Moreover, 
the CTC detection rate in advanced CRC patients during 
2 ~ 6 cycles chemotherapy was 49% (48 of 98 patients), 
which was significantly higher than that detected by Cell-
Search system (data showed in meta-analysis) [23, 24], 
and it was consistent with the results of another study 
which compared CTC detection rate of the size-based 
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platform and the CellSearch system in esophageal car-
cinoma [25]. The high sensitivity of this size-based plat-
form could be mainly attributed to two factors: Firstly, 
the CellSearch system only regarded tumor cells with epi-
thelial phenotype in peripheral blood as CTCs, which did 
not take other properties and processes which were asso-
ciated with malignant potential into consideration, such 
as EMT, cohesive and collective cell migration [22]. Sec-
ondly, this size-based platform captured malignant cells 
by the difference of diameter and deformability between 
abnormal cells and haemocytes, hence it could isolate 
more abnormal cells for further identifying CTCs. How-
ever, when comparing the CTC detection rates by ISET 
(isolation by size of epithelial tumor cells) in some studies 
[26–29], there was a subtle difference in this study. The 
discrepancy might due to the heterogeneity of different 
cancers, different stages of tumor, and whether undergo-
ing treatment or not, etc.
Fig. 2 The relationship between CTCs/CTM and clinicopathological characteristics in advanced CRC. a Serum CEA levels in CTC-positive patients 
were higher than CTC-negative patients (P = 0.0155). b There was no statistical significance in serum CA199 levels between CTC-positive and CTC-
negative patients (P = 0.0887). c The correlation of CTC count with tumor de-differentiation (poor vs. middle, P = 0.0191; poor vs. high, P = 0.0359). 
d CTC count of patients with depth of invasion (T4a vs. T4b, P = 0.7826; T4a vs. T3, P = 0.3708; T4a vs. T1 + T2, P = 0.4762). e The correlation of CTC 
count with lymphatic invasion (N2b vs. N0, P = 0.0429; N2b vs. N1, P = 0.0361; N2b vs. N2a, P = 0.1037). f The correlation of CTC count with TNM 
stage (IVb vs. III, P = 0.0186; IVb vs. IVa, P = 0.1019). g CTC count of patients with CEA > 10 pg/ml was more than CEA ≤ 10 pg/ml (P = 0.0026)
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We also observed the relationship between CTCs and 
clinicopathological characteristics, as shown in Table  1. 
It was found that CTCs were associated with tumor de-
differentiation, lymphatic invasion, TNM stage, and 
serum CEA level, which were consistent with the results 
of previous studies [30, 31]. In addition, serum CEA val-
ues in CTCs-positive patients were higher than CTCs-
negative patients, which indicated that patients with high 
CEA levels had more opportunities to be CTCs-positive. 
Moreover, CTC count was increasing with decreasing 
tumor de-differentiation, increasing lymphatic invasion, 
TNM stage, and serum CEA level. Therefore, although 
the decisions on stage of disease still did not include the 
results of CTC assessment, the presence of CTCs might 
be an adjunct to staging [32], and it could be expected 
that CTC detection predicted the properties and pro-
cesses of the disease (e.g. lymphatic invasion, TNM stage, 
and serum CEA level).
This study found that the presence of CTCs was associ-
ated with decreased survival in advanced CRC patients 
with 2–6 cycles chemotherapy, and Cox regression analyses 
showed that CTC detection was an independent prognos-
tic factor for survival, which was consistent with previous 
studies [23, 24, 33, 34]. Notably, it was reported that the 
Table 2 Univariate and multivariate analysis of prognostic factors for progression-free survival (PFS) and overall survival 
(OS) in advanced colorectal cancer
Italic values indicate statistically significant associations
* P < 0.05, *** P < 0.001
PFS OS
HR 95% CI P HR 95% CI P
Univariate analysis
Gender
Male vs. Female 1.242 0.746 2.070 0.404 0.907 0.540 1.523 0.711
Age
<60 vs. ≥60 0.959 0.572 1.608 0.875 0.977 0.593 1.612 0.929
Tumor size
<5 vs. ≥5 1.173 0.708 1.944 0.535 0.766 0.465 1.259 0.293
Location
Colon vs. Rectum 0.945 0.564 1.584 0.831 1.331 0.809 2.190 0.261
Differentiation
Well vs. Middle vs. Poor 0.746 0.521 1.068 0.109 1.000 0.696 1.437 0.999
T
T1+T2 vs. T3 vs. T4a vs. T4b 1.164 .871 1.555 0.304 1.081 .810 1.442 0.597
N
N0 vs. N1 vs. N2a vs. N2b 1.255 1.009 1.562 0.042* 1.507 1.210 1.875 <0.001***
TNM
II+III vs. IVa vs. IVb 2.027 1.383 2.971 <0.001*** 1.552 1.091 2.207 0.015*
CEA (ng/ml)
≤10 vs. >10 1.828 1.070 3.121 0.027* 1.452 0.884 2.385 0.141
CA199 (U/ml)
≤37 vs. >37 1.620 0.973 2.698 0.064 1.123 0.684 1.842 0.647
CTCs
Negative vs. Positive 2.870 1.716 4.801 <0.0001*** 1.664 1.003 2.761 0.048*
Multivariate analysis
N
N0 vs. N1 vs. N2a vs. N2b 1.169 0.930 1.469 0.180 1.499 1.198 1.876 <0.001***
TNM
II + III vs. IVa vs. IVb 1.687 1.115 2.553 0.013* 1.580 1.086 2.298 0.017*
CEA (ng/ml)
≤10 vs. >10 1.258 0.712 2.224 0.429
CTCs
Negative vs. Positive 1.993 1.141 3.483 0.015* 1.148 0.679 1.943 0.606
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relationship between CTC detection and prognosis was 
more significant and convincing when the blood samples 
were collected during treatment than at baseline [23, 24], 
which indicated that sample collection during treatment 
was preferable for CTC detection to predict CRC patient’s 
outcomes. That was the reason why we recruited the 
advanced CRC patients with 2–6 cycles chemotherapy in 
this study. Moreover, CTM was captured by this size-based 
platform, and CTM-positive patients with advanced CRC 
had worse survival than isolated CTCs-positive patients. It 
was reported that tumor cells within CTM could be pro-
tected from anoikis and were relatively resistant to cyto-
toxic drugs [35], and CTM was an independent prognostic 
factor [35, 36]. Hence, CTM would be more malignant and 
aggressive than isolated CTCs.
CTCs were comprised of heterogeneous cells including 
epithelial tumor cells, tumor cells undergoing EMT and 
tumor stem cells etc. [12, 37, 38], and circulating epithe-
lial tumor cells had been shown to respond to therapy 
in the same way as the primary tumor [39], while the 
detection of EMT markers (LOXL3 and ZEB2) for CTCs 
in mCRC predicted poor survival and therapy response 
during treatment [40], hence CTC molecular charac-
terization could offer the potential to better understand 
the biology of metastasis and resistance to established 
therapies [19]. In this study CTC phenotype was meas-
ured by immunofluorescent staining for CK8/18/19 (epi-
thelial marker) and vimentin (mesenchymal marker), and 
it was found that all CTM were vimentin-positive, while 
most of the isolated CTCs were CK-positive. Moreover, 
patients with vimentin+ CTCs had worse survival than 
CK+ CTCs. To our knowledge, this was the first study 
that evaluated the prognostic role of CTCs with epithelial 
and mesenchymal phenotype in advanced CRC patients 
during treatment.
Conclusion
In this study, it was found that the presence of CTCs was 
associated with decreased survival, and was an inde-
pendent prognostic factor for outcome in advanced CRC 
patients during chemotherapy. Moreover, patients with 
CTM had shorter survival than those with isolated CTCs, 
and patients with vimentin+ CTCs had worse survival 
compared to those with CK+ CTCs. Therefore, this study 
Fig. 3 The relationship between CTCs/CTM and PFS/OS in advanced CRC. a, b The PFS and OS of CTC-positive patients were shorter than CTC-neg-
ative patients (P = 0.0006, P = 0.0278). c, d The PFS and OS of CTC-positive patients were worse than CTM-positive patients (P = 0.0052, P = 0.0228)
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Fig. 4 The relationship between vimentin+ CTCs and PFS/OS in advanced CRC. The captured tumor cells were stained with anti-CK8/18/19 
antibody for epithelial marker (green fluorescence), anti-vimentin antibody for mesenchymal marker (yellow fluorescence), anti-CD45 antibody for 
leukocytes (red fluorescence), and hoechst for nucleus (blue fluorescence). The CTM detected in peripheral blood of patients were CK+/Vimentin+/
CD45− (a) or CK−/Vimentin+/CD45− (b) phenotype. The isolated CTCs were CK−/Vimentin+/CD45− (c) and CK+/Vimentin−/CD45− (d) pheno-
type. e, f Patients with vimentin+ CTCs had worse PFS/OS compared with CK+ CTCs (P = 0.0314, P = 0.0147)
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had demonstrated that CTM and vimentin+ CTCs could 
be used to improve prognostic value of CTCs in advanced 
CRC patients under treatment.
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